Viking Therapeutics, Inc. (VKTX) fair value analysis
Nasdaq · Updated 2026-10-19
VKTX price how computed
Valuation status
No fair-value estimate yetVKTX has no usable analyst consensus for next fiscal year's earnings, or too few reported quarters for our trailing P/E history.
Forward Fair Value needs both, so TickrTrends publishes no verdict for VKTX yet. We re-check every week; the price, fundamentals, technicals and earnings data below are unaffected.
- Last price
- $25.17
- Sector
- Healthcare
- 12-month range
- $25.17–$42.13
- Market cap
- $3.2B
- From 52-week high
- -40.3%
- Shares outstanding
- 127M
- Rank in Healthcare by quality score
- #274 of 301
Last price is the 2026-10-16 close; the chart runs through 2026-10-16.
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders. The company is based in the United States and conducts its research and development operations primarily through its headquarters and research facilities.
VKTX currently ranks #274 of 301 Healthcare stocks by quality score.
Fundamentals (4 quarters) how computed
- Market cap
- $3.2B
- P/E (trailing)
- n/m
- EPS (TTM)
- $-4.66
- Debt / equity
- 0.01
- Shares outstanding
- 127M
Derived indicators how computed
- Quality grade
- F
- 52-week position
- The bottom quarter of its range
Technicals how computed
- RSI (14-day)
- 43 · neutral
- 50-day average
- $32.17
- 200-day average
- $32.76
- Moving-average state
- 50-day below 200-day (death cross state); price below both averages
Earnings how computed
- Next earnings report
- 2026-10-28
- Last 8 quarters vs consensus
- 2 beat, 6 missed
- Quarter by quarter
- 2026-06 ▲ beat (+9.1%)
2026-03 ▼ miss (-50.5%)
2025-12 ▼ miss (-53.3%)
2025-09 ▼ miss (-20.9%)
2025-06 ▼ miss (-31.8%)
2025-03 ▼ miss (-32.3%)
2024-12 ▼ miss (-18.5%)
2024-09 ▲ beat (+8.3%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 18 buy · 2 hold · 0 sell (20 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $94.5
- Target vs last price
- +275.4%
What our data shows for VKTX
- Shares are trading in the lower third of their 12-month price range of $25.17–$42.13.
- The 14-day relative strength index sits at a neutral 43.
What subscribers see
- Every published Forward Fair Value with its exact discount or premium
- The normalized P/E and quarter count behind each estimate
- Screeners and rankings across the full S&P 500 and Nasdaq universes
- VKTX's own verdict the week it qualifies, published automatically
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
What people are saying
Follow the VKTX conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — # VKTX Weekly Indicator Summary VKTX's 50/200-day trend state has shifted from mixed to downtrend this week, reflecting weakening near-term price momentum relative to longer-term direction. The Healthcare sector stock remains under valuation review as TickrTrends awaits completion of its full valuation assessment.
- 2026-10-06 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-05 — VKTX moved from an uptrend to a mixed trend state in its 50/200-day analysis this week. The stock remains in the Healthcare sector with a valuation verdict of awaiting full valuation.
- 2026-09-28 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.
Frequently asked questions
Is VKTX stock undervalued?
TickrTrends has no fair-value estimate for VKTX yet: there is no usable analyst consensus for next fiscal year's earnings, or too few reported quarters for a trailing P/E history. It is re-checked every week.
What is VKTX's TickrTrends verdict?
VKTX is currently marked 'No fair-value estimate yet' - a verdict publishes automatically once a forward earnings consensus and enough reported quarters are available.
How does VKTX compare to other Healthcare stocks?
VKTX ranks #274 of 301 Healthcare stocks in TickrTrends' coverage by quality score. It carries no fair-value verdict yet, so it is not ranked by discount.
Is VKTX overbought or oversold?
VKTX's 14-day RSI is in neutral territory - neither overbought nor oversold.
When does VKTX report earnings next?
VKTX's next earnings report is scheduled for 2026-10-28, per the published earnings calendar.
Does VKTX usually beat earnings estimates?
Over its last 8 reported quarters VKTX beat the consensus estimate 2 times and missed 6 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about VKTX?
Of 20 analysts covering VKTX, 18 rate it a buy, 2 a hold and 0 a sell - buy-leaning, with a consensus price target of $94.5 (+275.4% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.